Law Offices of Thomas J. Lamb

  • Asbestos & Mesothelioma
  • Benzene Diseases
  • Drug Injury
  • About Our Firm
  • Free Case Evaluation
  • Frequently Asked Questions

Xeljanz Safety Alert for People Who Are (1) Older, (2) Current / Past Smokers, or (3) With Cardiovascular or Cancer Risk Factors

January 21, 2022 By Law Offices of Thomas J. Lamb, P.A.

This excerpt from the “Advisory – Health Canada safety review finds link between the use of Xeljanz and Xeljanz XR (tofacitinib) and increased risk of serious heart-related issues and cancer” issued in January 2022 provides an overview of the Xeljanz drug safety issue, and how the Xeljanz side effects risks may also apply to Olumiant and … [Read more...]

Filed Under: Unsafe Drugs Tagged With: cancers, cardiovascular events, heart problems, lung cancer, lymphoma, Myocardial Infarction, Olumiant, Rinvoq, Xeljanz

Cancers, Blood Clots, Heart Problems, and Deaths Associated with Xeljanz, Olumiant, and Rinvoq

December 15, 2021 By Law Offices of Thomas J. Lamb, P.A.

We continue to monitor the pharmaceutical regulatory sector as well as the medical literature for developments as regards the increased risks of cancers, blood clots, heart problems, and deaths associated with Xeljanz, Olumiant, and Rinvoq. In December 2021 there was another JAK inhibitors drug class safety development, with Xeljanz, Olumiant, … [Read more...]

Filed Under: Unsafe Drugs Tagged With: blood clots, cancers, heart problems, Olumiant, Rinvoq, Xeljanz

Imbruvica Heart-Related Side Effects and Cardiotoxicity Safety Issues

October 8, 2021 By Law Offices of Thomas J. Lamb, P.A.

In this article, we point out a few of the medical news reports about heart-related Imbruvica side effects that have been published in the past 12 months. First, there is this November 2020 Healio article, “Link between ibrutinib-related hypertension, heart problems necessitates close monitoring”, which provides some key findings from several … [Read more...]

Filed Under: Unsafe Drugs Tagged With: atrial fibrillation, Heart Failure, heart problems, Imbruvica

Xeljanz: Heart Attacks, Strokes, Cancers, Blood Clots, and Deaths – Updated FDA Warnings 2021

September 7, 2021 By Law Offices of Thomas J. Lamb, P.A.

On September 1, 2021, we saw new FDA Xeljanz warnings about the increased risks of heart attacks, strokes, cancer, blood clots, and deaths. These Xeljanz drug safety problems have been associated with all doses of Xeljanz (5 mg tablet and 10 mg tablet) and Xeljanz XR (11 mg tablet and 22 mg tablet). This September 2021 document, “FDA requires … [Read more...]

Filed Under: Unsafe Drugs Tagged With: cancer, Heart Attacks, heart problems, Strokes, Xeljanz

Possible FDA Advisory Committee Meeting for Xeljanz, Olumiant, and Rinvoq in Future

April 20, 2021 By Law Offices of Thomas J. Lamb, P.A.

Based on these several recent developments, we expect that there will be an FDA Advisory Committee Meeting for Xeljanz, Olumiant, and Rinvoq in the months to come. The focus of such will likely be these adverse drug events and side effects related to the JAK inhibitors class of drugs: Heart AttacksMyocardial Infarction (MI)Strokes — Ischemic / … [Read more...]

Filed Under: Unsafe Drugs Tagged With: cancer, heart problems, Olumiant, Rinvoq, Xeljanz

Are Heart Problems and Cancers JAK Inhibitors Drug Class Safety Issues?

March 30, 2021 By Law Offices of Thomas J. Lamb, P.A.

Since the February 2021 FDA alert about Xeljanz-associated heart problems and possible Xeljanz-related cancers was issued, we have been watching for any related drug safety developments concerning Olumiant and Rinvoq. The reason being there has been some concern that those adverse drug events and side effects risks may apply to those other two … [Read more...]

Filed Under: Uncategorized, Unsafe Drugs Tagged With: cancer, heart problems, JAK inhibitors, Olumiant, Rinvoq, Xeljanz

Find What You Want Here

Get Free Case Evaluation

We encourage you to submit an online Case Evaluation Form form – it is confidential and there is no obligation.

Or call our toll-free number, 800-426-9535, to speak directly to attorney Tom Lamb about your possible case.

Feel Free To Contact Us

Quick Contact Form
 
Send an Email to Tom Lamb

(800) 426-9535

Main Navigation Menu

  • About Our Firm
  • Asbestos-Mesothelioma Cases
  • Benzene Disease Claims
  • Drug Injury Cases
  • Breast Implant Cases
  • Philips Breathing Devices Cases
  • GenX Cancer Cases
  • Case Evaluation Menu
  • Quick Contact Form
  • Frequently Asked Questions
  • Medical Records Charges
  • Collection of Articles
  • Sitemap

Lamb Law Office Newsletter

Lamb Law Office Newsletter provides periodic updates about some of the cases that we are working on for clients, as well as an information resource you might find helpful.

Subscribe using Form below.

Subscription Form

* indicates required

Our Other Websites

Drug Injury Law
Drug Injury Watch
Drug Safety Developments
Asbestos & Mesothelioma

Contact Information

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, North Carolina 28403
910-256-2971 | 800-426-9535
TJL@LambLawOffice.com

  • Home
  • Frequently Asked Questions
  • Disclaimer and Copyright Notices

Copyright © 2022 · Law Offices of Thomas J. Lamb, P.A.